Pharmaceutical Technology

NOVEMBER 22, 2023

Myricx Bio has signed a licence agreement for contract research, development and manufacturing organisation WuXi Biologics’ antibody.

Antibody 130

Antibody Manufacturing Research Development 130

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Drugs Licensing 217

Pharmaceutical Technology

MAY 15, 2023

Sanofi announced data from a real-world clinical trial that demonstrated its RSV antibody nirsevimab delivered an 83% reduction in hospitalisations in infants with respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD). Nirsevimab is being jointly developed between Sanofi and AstraZeneca.

Antibody 245

Antibody Clinical Trials Clinical Trials Vaccination 245

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Clinical Trials Clinical Trials Drugs 264

Drug Discovery World

NOVEMBER 2, 2023

This brought us to intersect with AION Labs, which had issued a call for applicants to launch a new company leveraging AI-based solutions for the computational de novo design of high-affinity antibodies for targeted therapies. RA: How laborious and expensive are current antibody discovery efforts? KS: In short, incredibly so.

Antibody 83

Antibody Protein Drugs Development 83

Pharmaceutical Technology

OCTOBER 12, 2023

Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

OCTOBER 17, 2023

LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).

Antibody 130

Antibody Drugs Development Licensing 130

Pharmaceutical Technology

MAY 24, 2023

HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.

Antibody 147

Antibody Clinical Development Development Research 147

Pharmaceutical Technology

SEPTEMBER 21, 2023

AbCellera and Regeneron have extended their current multi-target collaboration to discover therapeutic antibodies for up to eight targets

Antibody 130

Antibody 130

Pharmaceutical Technology

OCTOBER 10, 2023

The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.

Antibody 147

Antibody Development Protein 147

Pharmaceutical Technology

OCTOBER 6, 2023

Genomics company Twist Bioscience has entered into an antibody discovery, option and licence agreement with German drug manufacturer Bayer.

Antibody 130

Antibody Genome Genomics Drugs 130

Pharmaceutical Technology

OCTOBER 20, 2023

The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.

Antibody 147

Antibody Development Trials 147

Pharmaceutical Technology

OCTOBER 5, 2023

IMIDomics and WuXi Biologics have signed an agreement to advance the development and manufacturing of the humanised antibody, IMB1001

Antibody 130

Antibody Development Manufacturing 130

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Drugs Licensing 279

Bio Pharma Dive

APRIL 21, 2023

A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.

Antibody 193

Antibody Drugs Marketing 193

Pharmaceutical Technology

SEPTEMBER 14, 2023

AbCellera and Incyte have entered a partnership for the discovery and development of therapeutic antibodies in oncology.

Antibody 147

Antibody Development 147

Bio Pharma Dive

AUGUST 28, 2023

The acquisition gives Danaher ownership of a producer of research tools, such as antibodies and reagents, that are used in drug discovery experiments.

Antibody 130

Antibody Reagent Drugs Research 130

Pharmaceutical Technology

SEPTEMBER 28, 2023

Ono Pharmaceutical and Adimab have signed a drug discovery collaboration agreement for the development of antibody drugs in oncology

Antibody 130

Antibody Drugs Development 130

pharmaphorum

NOVEMBER 28, 2023

Boehringer puts IBM's genAI into its antibody discovery tank Phil.Taylor Tue, 28/11/2023 - 11:18 Bookmark this

Antibody 105

Antibody 105

Pharmaceutical Technology

DECEMBER 6, 2022

The three leading Alzheimer’s disease (AD) drugs currently in development are all monoclonal antibodies—donanemab by Eli Lilly , lecanemab by Eisai and Biogen , and gantenerumab by Roche. Monoclonal antibodies make up half of these, with an 11% share of all AD approvals.

Antibody 147

Antibody Marketing Drugs Trials 147

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Protein Medicine Drugs 147

Bio Pharma Dive

JUNE 16, 2021

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients.

Antibody 327

Antibody Trials 327

Pharmaceutical Technology

MARCH 20, 2023

BioNTech has signed an exclusive worldwide licence and collaboration agreement with OncoC4 to co-develop and commercialise a new checkpoint antibody in multiple solid tumour indications. BioNTech will solely develop all the combinations other than the PD-1 inhibition.

Antibody 246

Antibody Development Trials Drugs 246

Pharmaceutical Technology

SEPTEMBER 5, 2023

The Series C funding will support the clinical advancement of Vega Therapeutics’ antibody candidate for treating von Willebrand disease.

Antibody 130

Antibody 130

BioPharma Reporter

NOVEMBER 7, 2023

The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech companyâs bispecific antibody cancer drug PM8002 in all territories except for Greater China.

Antibody 98

Antibody Licensing Licensing Drugs 98

Bio Pharma Dive

NOVEMBER 5, 2020

Fast antibody testing, however, is spotty. The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

Antibody 304

Antibody Drugs 304

Pharmaceutical Technology

SEPTEMBER 1, 2023

Twist and Ono will discover and develop novel antibodies to treat autoimmune diseases and generate comprehensive discovery campaigns.

Antibody 130

Antibody Development 130

Bio Pharma Dive

JUNE 18, 2021

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.

Antibody 346

Antibody Drugs 346

Pharmaceutical Technology

JULY 3, 2023

Chime Biologics, Leads Biolabs and BeiGene have entered a strategic partnership to expedite the development of a monoclonal antibody, LBL-007.

Antibody 130

Antibody Development 130

BioPharma Reporter

NOVEMBER 9, 2023

The antibody drug nipocalimab, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, has shown early promise for treating rheumatoid arthritis (RA) in a phase 2a trial.

Antibody 105

Antibody Drugs Protein Trials 105

BioSpace

OCTOBER 31, 2023

The regulator has released Mersana Therapeutics’ antibody-drug conjugate XMT-2056 from its clinical hold, allowing the biotech to proceed with Phase I studies of the candidate with a lower starting dose.

Antibody 112

Antibody Drugs Regulation 112

Bio Pharma Dive

FEBRUARY 10, 2021

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death.

Antibody 304

Antibody Drugs 304

Pharmaceutical Technology

JULY 12, 2023

Crossbow Therapeutics has raised Series A funds worth $80m to develop a new class of antibody treatments for cancer.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

JULY 31, 2023

US FDA and China’s NMPA have approved the Phase I trial of anti-GPRC5D/CD3 bispecific antibody (LBL-034) by Leads Biolabs.

Antibody 130

Antibody FDA Approval Trials 130

Drug Discovery World

JULY 21, 2023

Under the terms of the agreement, Cancer Research Horizons will license Twist’s ‘Library of Libraries’, an collection of synthesised antibody libraries designed based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of antibody drug targets, for a period of five years.

Antibody 98

Antibody Research Drugs Licensing 98